Metformin + GLP-1 receptor agonists

Intervention

1 paper3 findings

  • 1 lab in 2 countries
  • Humans1

Associations

3

Alzheimer's disease

downin humans1HR 0.46

1 study
  1. Metformin + GLP-1 receptor agonists lower the risk of Alzheimer's disease in humans (HR 0.46, 95% CI 0.31-0.70).

    Humanstype 2 diabetes, versus metformin only

    Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study

    PloS one24 Aug 2026

More on Alzheimer's disease

Mild cognitive disorder

downin humans1HR 0.79

1 study
  1. Metformin + GLP-1 receptor agonists lower the risk of mild cognitive disorder in humans (HR 0.79, 95% CI 0.66-0.95).

    Humanstype 2 diabetes, versus metformin only

    Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study

    PloS one24 Aug 2026

More on Mild cognitive disorder

Vascular dementia

downin humans1HR 0.46

1 study
  1. Metformin + GLP-1 receptor agonists lower the risk of vascular dementia in humans (HR 0.46, 95% CI 0.37-0.57).

    Humanstype 2 diabetes, versus metformin only

    Antidiabetic medications and risk of cognitive disorders in type 2 diabetes: A retrospective cohort study

    PloS one24 Aug 2026

More on Vascular dementia

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 01 in 12 months